JPRN-jRCT2041210052暂停2 期
[M20-466] A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)
Yamazaki Hayato0 个研究点目标入组 425 人开始时间: 2021年8月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- 入组人数
- 425
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Clinical diagnosis of rheumatoid arthritis(RA) with fulfillment of the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA.
- •--Participant has 6 swollen joints (based on 66 joint count) and 6 tender joints (based on 68 joint count) at baseline.
- •--Participant must have had an inadequate response to at least one prior biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) treatment for RA.
- •--Participants must be on stable dose of methotrexate (MTX).
排除标准
- •--Participant discontinued prior adalimumab therapy due to intolerability or toxicity.
研究者
相似试验
招募中
2 期
[M19-148] A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic StrokeAcute Ischemic StrokeJPRN-jRCT2061210064Otani Tetsuya120
招募中
2 期
[M16-077] A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord InjuryAcute Traumatic Cervical Spinal Cord InjuryJPRN-jRCT2031210009Otani Tetsuya54
暂停
2 期
[M20-371]Moderate to Severe Crohn's Disease: A Phase 2 Safety and Efficacy Study of ABBV-154Crohn's diseaseJPRN-jRCT2051210135Yamazaki Hayato265
进行中（未招募）
3 期
[M16-191] Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMyelofibrosisJPRN-jRCT2041210045Okubo Sumiko23
Unknown
不适用
A randomized, double-blind, Placebo-controlled, three arms, parallel-group, multiple-site bioequivalence study with clinical endpointsCTRI/2018/11/016407Encube Ethicals Private Ltd13